|Institution:||CRUK Manchester Institute|
|Salary:||£31,604 - £41,929|
|Line 1:||CRUK Manchester Institute|
About the role:
The main goal of the Stem Cell Biology group is to identify new therapies for Acute Myeloid Leukaemia (AML). A 3 year position is available in the laboratory of Prof. Georges Lacaud to investigate genes and mechanisms involved in the initiation and/or maintenance of AML, and to further validate and progress them as potential therapeutic targets.
Leukaemia is the 8th most common cause of cancer death in Europe. Treatments of AML have not dramatically changed, or improved, in the last 30 years. Therefore, there is a pressing need for the development of more specific and efficient therapies. In this context, the group is particularly interested in investigating the role and requirements of transcription factors recurrently rearranged or mutated in human leukaemias such as the master regulator of blood development AML1/RUNX1 and the transcriptional co-activator MOZ.
You should have a PhD in molecular or cell biology (or a relevant field). Relevant experience in haematopoiesis or leukaemia working with cellular or in vivo models is essential. Bioinformatic skills are desirable. Key qualities should include independent thinking, ability to work in a team and good communication skills, all of which are needed to efficiently work in a multidisciplinary team.
Informal enquiries should be directed to Georges Lacaud via email: firstname.lastname@example.org.